The Diabetes business unit at Medtronic (NYSE:MDT) could have some exciting offering in the pipeline, company officials say.
Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...
Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...
In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback